


Amendments to the Claims

Claim 1. (Currently amended): Compounds having the structure of Formula I



FORMULA - I

and their pharmaceutically acceptable salts, enantiomers, diastereomers, N-oxides, or their polymorphs, wherein A is a straight or branched C₁-C₄ alkyl chain; R is cinnamyl, (dihalodiphenyl) methyl, benzyl, substituted benzyl, ~~mono- or disubstituted~~ monosubstituted phenyl group substituted with the substituents independently selected from the group consisting of hydroxy, nitro, or trifluoroalkoxy group, ~~or (dihalodiphenyl) methyl or disubstituted phenyl group substituted with the substituents independently selected from the group consisting of halogen, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, trifluoromethyl, nitro, or trifluoroalkoxy group.~~

Claim 2. (Cancelled)

Claim 3. (Currently amended): Compounds selected from the group consisting of:

- ~~2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 01);~~
- ~~2-[3-{4-(3-Chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 02).~~
- ~~2-[3-{4-(2-Methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 03).~~
- ~~2-[3-{4-(4-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 04);~~


- ~~2-[3-{4-(3-Trifluoromethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 05);~~
- ~~2-[3-{4-(2-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 06);~~
- ~~2-[3-{4-(3,4-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 07);~~
- ~~2-[3-{4-(2-Methoxy-5-fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 08);~~
- ~~2-[3-{4-(2-Ethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 09);~~
- ~~2-[3-{4-(2,4-Difluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 10);~~
- ~~2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 11);~~
- ~~2-[3-{4-(2-Methyl-5-chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 12);~~
- ~~2-[3-{4-(Phenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 13);~~
- ~~2-[3-{4-(Benzyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 14);~~
- ~~2-[3-{4-(Cinnamyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 15);~~
- ~~2-[3-{4-(4-Nitrophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 16);~~
- ~~2-[3-{4-(3-Chloro-4-methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 17);~~
- ~~2-[3-{4-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 18);~~
- ~~2-[3-{4-(Bis-4-fluorophenyl)methylpiperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 19);~~
- ~~2-[3-{4-(2,4-Dichlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 20);~~

- 2-[3-{4-(2,4-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 21);
- 2-[3-{4-(2,6-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 22);
- 2-[3-{4-(2-Isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 23);
- 2-[3-{4-(2-Propoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 24);
- 2-[3-{4-(2-n-Hexyloxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 25);
- 2-[3-{4-(2,5-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 26);
- ~~2-[3-{4-(4-tert-Butylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 27);~~

- 2-[3-{4-(2-Methoxy-6-hydroxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 28);
- ~~2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 29);~~
- ~~2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-2-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 30);~~
- ~~2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 31).~~

Claim 4. (Cancelled)

Claim 5. (Currently Amended): A method for treating benign prostatic hyperplasia in a mammal comprising administering to said mammal a compound having the structure of Formula I



FORMULA - I


or its pharmaceutically acceptable salts, enantiomers, diastereomers, N-oxides, or their polymorphs, wherein A is a straight or branched C₁-C₄ alkyl chain; R is cinnamyl, (dihalodiphenyl) methyl, benzyl, substituted benzyl, phenyl, mono- or disubstituted with the substituents independently selected from the group consisting of halogen, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, trifluoromethyl, nitro, or trifluoroalkoxy group, ~~or (dihalodiphenyl) methyl.~~

Claim 6. (Previously amended): A pharmaceutical composition comprising a compound of claims 1 or 3 and a pharmaceutical acceptable carrier.

Claim 7. (Cancelled)


Claim 8. (Previously amended): A method for treating benign prostatic hyperplasia in a mammal comprising administering to said mammal, the pharmaceutical composition according to claim 6.

Claim 9. (Currently Amended): A process for preparing compounds of Formula I




FORMULA - I

and their pharmaceutically acceptable salts, enantiomers, diastereomers, N-oxides, or their polymorphs, wherein A is a straight or branched C₁-C₄ alkyl chain; R is cinnamyl, (dihalodiphenyl) methyl, benzyl, substituted benzyl, mono- or disubstituted phenyl group substituted with the substituents independently selected from the group consisting of hydroxy, nitro, or trifluoroalkoxy group, ~~or (dihalodiphenyl)-methyl~~, comprising reacting cis 1,2,3,6-tetrahydrophthalic anhydride of Formula II



FORMULA II


with 1-amino-4-substituted piperazinyl alkane of Formula III,



FORMULA III

wherein A and R are as defined above, in the presence of a solvent selected from the group consisting of pyridine, n-butanol, benzene and xylene.


Claim 10. (Currently Amended): A process for preparing compounds of Formula I



FORMULA - I


and their pharmaceutically acceptable salts, enantiomers, diastereomers, N-oxides, or their polymorphs, wherein A is a straight or branched C₁-C₄ alkyl chain; R is cinnamyl, or (dihalodiphenyl) methyl, benzyl, substituted benzyl, phenyl, mono- or disubstituted phenyl group substituted with the substituents independently selected from the group consisting of halogen, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, trifluoromethyl, nitro, or trifluoroalkoxy group or (dihalodiphenyl) methyl, comprising reacting

1-(ω-haloalkyl)cis-3a,4,7,7a-tetrahydrophthalimide of Formula IV, wherein A is as defined above,



FORMULA IV

with 1-substituted piperazine of Formula V,



FORMULA V

wherein R is as defined above.